Immunosuppressive measures for CRS have been shown to decrease progression to more severe CRS and did not negatively impact the anti-leukemic efficacy of CD19 CAR-T therapy or disease-free survival [60,61]. This evidence concerns the gene CD19 and congenital rubella syndrome.